Figure 4.

Rosiglitazone fails to normalize markers of β-cell dedifferentiation. A: Intraperitoneal glucose tolerance test after rosiglitazone treatment. B: Area under the curve (AUC) of intraperitoneal glucose tolerance test shown in panel A. C: Body weight after rosiglitazone treatment. D: Plasma insulin levels after rosiglitazone treatment. E: Total islet cell number after rosiglitazone treatment (rosiglitazone vs. vehicle, P = 0.0159). Representative image of Foxo1/insulin coimmunostaining (F) and cell number (G). Representative image (H) and number (I) of Aldh1a3-positive/insulin-positive cells. Representative image (J) and proportion (K) of glucagon/insulin-positive cells. Data show means ± SEM. (n = 3–4 for each group.) P values were calculated by t test for A–D and F–K and Mann-Whitney U test for E. *P < 0.05 and **P < 0.01 between the denoted pairs. cont, control; Gcg, glucagon; Ins, insulin; Rosi, rosiglitazone; w, wild type.